Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva

Castro, D.; Miranda, P.; Sánchez-Ballester, F.; Arumí, Daniel; Ebel, Christine

doi:10.1016/j.acuro.2010.11.011

Cited by 18 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, many patients express a wish to change their treatment to another anticholinergic drug or another type of therapeutic [9]. Generally, the most common reasons for a change of the medication are a lack of therapeutic response, new medications, side effects, and the acceptance, by some patients, that their pathology is not going to improve no matter which treatment they receive [10].…”

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation

et al. 2012

View full text Add to dashboard Cite

Purpose Overactive bladder (OAB) is a clinical syndrome that is currently treated initially with anticholinergics, although some other therapeutic alternatives exist, such as neuromodulation, botulinum toxin, and posterior tibial nerve stimulation (PTNS). The purpose of this study was to assess the efficacy of PTNS in patients with OAB refractory to anticholinergics. Materials and Methods We present a cohort study of 14 women with OAB to whom we applied PTNS. We assessed (before and after the treatment) the diurnal micturitional frequency, the nocturnal micturitional frequency, urgency episodes, and urge incontinence episodes. Results were analyzed by using the Wilcoxon test for nonparametric samples. Results We observed statistically significant improvement in the diurnal micturitional frequency (p=0.05), in episodes of micturitional urgency (p=0.03), and in episodes of urge incontinence (p=0.004). A total of 50% of the patients felt subjective improvement from their pathology. Conclusions PTNS is a valid, minimally invasive treatment option with minimum morbidity for patients with OAB refractory to treatment with anticholinergics.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The probability of discontinuation due to AEs was assumed to be 90% as no published data were available for this parameter. The probability of discontinuation for other reasons (6.8%) was estimated from the literature [23,24]. The probability of treatment switch after discontinuation (26.1%) was taken from a UK study [25], and the probability of restarting treatment among patients who discontinued treatment without immediate treatment switch was assumed in the absence of published data (5.6%).…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Hakimi

Kelleher

Aballéa

et al. 2018

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period. Results: Solifenacin 5 mg/day was the dominant treatment strategy (i.e., less costly and more effective) versus tolterodine extended-release (ER) 4 mg/day, fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day and solifenacin 10 mg/day, and was cost-effective (i.e., ICERs below the £30,000 per QALY threshold generally applied in the NHS) versus oxybutynin immediate release (IR) 10 mg/day, tolterodine IR 4 mg/day and trospium chloride 60 mg/day. The probability of solifenacin 5 mg/day being dominant/cost-effective at a willingness-to-pay threshold of £30,000 per QALY was 57–98%. Conclusions: Solifenacin 5 mg/day appears to be a cost-effective strategy for the treatment of OAB over a 5-year timeframe compared with other oral antimuscarinic agents in the UK. These findings are important for decision-makers considering the economic implications of selecting treatments for OAB.

show abstract

“…About half of reviewed complied with the new treatment. Over 65% showed improvement with respect to their previous treatment, 60% were quite/very satisfied with current treatment, 91% preferred it to their previous treatment and 93% reported that their symptoms had improved [ 13 ].…”

Section: The Lower Urinary Tract Stores and Evacuates Urine It Is Comentioning

confidence: 99%

Featured paper Postmenopausal overactive bladder

Tomaszewski¹

2014

View full text Add to dashboard Cite

Bladder storage symptoms have a severe impact on many areas as regards the quality of life including health-related, social, psychological and working functions. Pharmacotherapy of lower urinary tract stores (LUTS) has been developed to optimize neural control of the lower urinary tract in pathologic states. The bladder can be overactive or underactive. Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity, especially in aging population. Therefore, an effective treatment of OAB must result in a meaningful reduction in urinary symptoms. Pharmacotherapy for the OAB must be individualized based on the degree of bother, medication side-effect profile, concomitant comorbidities and current medication regimen. Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB. Alternatively to antimuscarinic therapy, β3-adrenergic receptor agonists, due to their efficacy and favorable adverse event profile, are a novel and attractive option of pharmacological treatment of overactive bladder symptoms. A combination of selective antimuscarinic and β3-adrenergic receptor agonists, agents with the different mechanism of action, gives a new treatment option for the patient with OAB according to its harms profile. A number of putative novel therapeutic agents is under clinical evaluations that may ultimately provide alternative or combination treatment options for OAB in the nearest future.

show abstract

Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva

Cited by 18 publications

References 27 publications

Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation

Clinical Efficacy in the Treatment of Overactive Bladder Refractory to Anticholinergics by Posterior Tibial Nerve Stimulation

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Featured paper Postmenopausal overactive bladder

Contact Info

Product

Resources

About